<?xml version='1.0' encoding='utf-8'?>
<document id="20094773"><sentence text="Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)."><entity charOffset="97-107" id="DDI-PubMed.20094773.s1.e0" text="paclitaxel" /><entity charOffset="112-123" id="DDI-PubMed.20094773.s1.e1" text="carboplatin" /><entity charOffset="138-147" id="DDI-PubMed.20094773.s1.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.20094773.s1.e0" e2="DDI-PubMed.20094773.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s1.e0" e2="DDI-PubMed.20094773.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s1.e0" e2="DDI-PubMed.20094773.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20094773.s1.e1" e2="DDI-PubMed.20094773.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s1.e1" e2="DDI-PubMed.20094773.s1.e2" /></sentence><sentence text="To assess the pharmacokinetics and evaluate potential drug-drug interactions between erlotinib, paclitaxel and carboplatin"><entity charOffset="85-94" id="DDI-PubMed.20094773.s2.e0" text="erlotinib" /><entity charOffset="96-106" id="DDI-PubMed.20094773.s2.e1" text="paclitaxel" /><entity charOffset="111-122" id="DDI-PubMed.20094773.s2.e2" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20094773.s2.e0" e2="DDI-PubMed.20094773.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s2.e0" e2="DDI-PubMed.20094773.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s2.e0" e2="DDI-PubMed.20094773.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20094773.s2.e1" e2="DDI-PubMed.20094773.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s2.e1" e2="DDI-PubMed.20094773.s2.e2" /></sentence><sentence text="" /><sentence text="1,079 previously untreated patients with advanced NSCLC were enrolled and randomized in a phase III trial (TRIBUTE) to receive either erlotinib or placebo in combination with paclitaxel 200 mg/m2 IV over 3 h and carboplatin at a calculated dose to achieve an AUC 6 mg∙min/mL"><entity charOffset="134-143" id="DDI-PubMed.20094773.s4.e0" text="erlotinib" /><entity charOffset="175-185" id="DDI-PubMed.20094773.s4.e1" text="paclitaxel" /><entity charOffset="212-223" id="DDI-PubMed.20094773.s4.e2" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20094773.s4.e0" e2="DDI-PubMed.20094773.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s4.e0" e2="DDI-PubMed.20094773.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s4.e0" e2="DDI-PubMed.20094773.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20094773.s4.e1" e2="DDI-PubMed.20094773.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s4.e1" e2="DDI-PubMed.20094773.s4.e2" /></sentence><sentence text=" To determine possible drug-drug interaction with this combination, a subset of 24 (12 erlotinib, 12 placebo) patients were enrolled onto an intensive pharmacokinetic (IPK) substudy group at a single site" /><sentence text=" All IPK patients received either erlotinib 150 mg/day or placebo-controlled tablets"><entity charOffset="34-43" id="DDI-PubMed.20094773.s6.e0" text="erlotinib" /></sentence><sentence text=" Analyses were completed using validated analytical methodologies" /><sentence text=" Non-compartmental modeling was utilized to estimate PK parameters" /><sentence text="" /><sentence text="Complete blood sampling for pharmacokinetic analysis was obtained in 21 of 24 patients" /><sentence text=" Mean AUC(0-τ) for erlotinib and the OSI-420 metabolite were 29,997 ng∙h/mL and 3,020 ng∙h/mL, respectively"><entity charOffset="19-28" id="DDI-PubMed.20094773.s11.e0" text="erlotinib" /><entity charOffset="37-44" id="DDI-PubMed.20094773.s11.e1" text="OSI-420" /><pair ddi="false" e1="DDI-PubMed.20094773.s11.e0" e2="DDI-PubMed.20094773.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s11.e0" e2="DDI-PubMed.20094773.s11.e1" /></sentence><sentence text=" Mean (SD) paclitaxel clearances (L/h/M(2)) were 11"><entity charOffset="11-21" id="DDI-PubMed.20094773.s12.e0" text="paclitaxel" /></sentence><sentence text="7 (3" /><sentence text="4) and 12" /><sentence text="7 (6" /><sentence text="7) in the placebo and erlotinib treatment groups, respectively"><entity charOffset="22-31" id="DDI-PubMed.20094773.s16.e0" text="erlotinib" /></sentence><sentence text=" The resultant paclitaxel AUC(0-∞) (ng∙h/mL) was 18,400 (5,300) for the placebo group and 17,800 (5,500) for the erlotinib group"><entity charOffset="15-25" id="DDI-PubMed.20094773.s17.e0" text="paclitaxel" /><entity charOffset="113-122" id="DDI-PubMed.20094773.s17.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.20094773.s17.e0" e2="DDI-PubMed.20094773.s17.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s17.e0" e2="DDI-PubMed.20094773.s17.e1" /></sentence><sentence text=" For carboplatin, the mean (SD) clearances (L/h) were 16"><entity charOffset="5-16" id="DDI-PubMed.20094773.s18.e0" text="carboplatin" /></sentence><sentence text="8 (3" /><sentence text="9) and 16" /><sentence text="1 (4" /><sentence text="4) for the placebo and erlotinib groups, respectively"><entity charOffset="23-32" id="DDI-PubMed.20094773.s22.e0" text="erlotinib" /></sentence><sentence text=" The resultant carboplatin AUC(0-∞) (ng/mL∙h) were 49,900 (9,700) for the placebo group and 48,400 (11,900) for the erlotinib group"><entity charOffset="116-125" id="DDI-PubMed.20094773.s23.e0" text="erlotinib" /></sentence><sentence text=" No significant differences were observed in these paclitaxel or carboplatin pharmacokinetic group comparisons"><entity charOffset="51-61" id="DDI-PubMed.20094773.s24.e0" text="paclitaxel" /><entity charOffset="65-76" id="DDI-PubMed.20094773.s24.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20094773.s24.e0" e2="DDI-PubMed.20094773.s24.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s24.e0" e2="DDI-PubMed.20094773.s24.e1" /></sentence><sentence text="" /><sentence text="The addition of erlotinib to a standard chemotherapy regimen for NSCLC did not alter the systemic exposures (AUC(0-∞)) of paclitaxel (p = 0"><entity charOffset="16-25" id="DDI-PubMed.20094773.s26.e0" text="erlotinib" /><entity charOffset="122-132" id="DDI-PubMed.20094773.s26.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.20094773.s26.e0" e2="DDI-PubMed.20094773.s26.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s26.e0" e2="DDI-PubMed.20094773.s26.e1" /></sentence><sentence text="80) and carboplatin (p = 0"><entity charOffset="8-19" id="DDI-PubMed.20094773.s27.e0" text="carboplatin" /></sentence><sentence text="756) when erlotinib-treated patients were compared to placebo-treated patients"><entity charOffset="10-19" id="DDI-PubMed.20094773.s28.e0" text="erlotinib" /></sentence><sentence text=" The pharmacokinetics of erlotinib and its metabolite OSI-420 did not appear to be altered by the concomitant administration of paclitaxel and carboplatin"><entity charOffset="25-34" id="DDI-PubMed.20094773.s29.e0" text="erlotinib" /><entity charOffset="128-138" id="DDI-PubMed.20094773.s29.e1" text="paclitaxel" /><entity charOffset="143-154" id="DDI-PubMed.20094773.s29.e2" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.20094773.s29.e0" e2="DDI-PubMed.20094773.s29.e0" /><pair ddi="false" e1="DDI-PubMed.20094773.s29.e0" e2="DDI-PubMed.20094773.s29.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s29.e0" e2="DDI-PubMed.20094773.s29.e2" /><pair ddi="false" e1="DDI-PubMed.20094773.s29.e1" e2="DDI-PubMed.20094773.s29.e1" /><pair ddi="false" e1="DDI-PubMed.20094773.s29.e1" e2="DDI-PubMed.20094773.s29.e2" /></sentence><sentence text="" /></document>